Last reviewed · How we verify
CV8102
At a glance
| Generic name | CV8102 |
|---|---|
| Sponsor | CureVac |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (PHASE1)
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (PHASE1, PHASE2)
- Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CV8102 CI brief — competitive landscape report
- CV8102 updates RSS · CI watch RSS
- CureVac portfolio CI